Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
2.58 (USD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0.29 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.436 | 0.73 | 0.151 | 0.226 |
| Cost of Revenue
| 0.045 | 0.044 | 0.039 | 0.04 | 0.053 | 0.052 | 0.049 | 0.044 | 0.039 | 0.037 | 0.003 | 0.001 | 2.254 | 2.531 | 1.026 | 2.994 | 1.927 | 2.05 |
| Gross Profit
| -0.045 | -0.044 | 0.251 | -0.04 | -0.053 | -0.052 | -0.049 | -0.044 | -0.039 | -0.037 | -0.003 | -0.001 | -2.254 | -2.531 | 0.41 | -2.264 | -1.776 | -1.824 |
| Gross Profit Ratio
| 0 | 0 | 0.866 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.286 | -3.101 | -11.762 | -8.071 |
| Reseach & Development Expenses
| 19.533 | 12.449 | 13.293 | 11.179 | 9.133 | 8.713 | 10.746 | 8.309 | 7.321 | 5.985 | 5.673 | 1.8 | 2.254 | 2.578 | 1.026 | 2.994 | 1.927 | 2.05 |
| General & Administrative Expenses
| 4.848 | 5.325 | 5.193 | 4.86 | 4.345 | 4.422 | 3.502 | 3.062 | 3.09 | 3.221 | 2.742 | 2.135 | 1.187 | 1.215 | 0.644 | 0.226 | 0.259 | 0.222 |
| Selling & Marketing Expenses
| -0.045 | 0 | -0.039 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 4.803 | 5.325 | 5.154 | 4.86 | 4.345 | 4.422 | 3.502 | 3.062 | 3.09 | 3.221 | 2.742 | 2.135 | 1.187 | 1.215 | 0.644 | 0.226 | 0.259 | 0.222 |
| Other Expenses
| -0.068 | -0.054 | -0.021 | -0.042 | -0.016 | -0.004 | -0.01 | -0.002 | 0 | 0.001 | 0.004 | 0.019 | 0.019 | 0.009 | 1.107 | 0 | 0 | 0 |
| Operating Expenses
| 24.336 | 17.774 | 18.447 | 16.039 | 13.478 | 13.135 | 14.248 | 11.371 | 10.411 | 9.206 | 8.415 | 3.935 | 3.441 | 3.793 | 2.777 | 2.49 | 2.186 | 2.272 |
| Operating Income
| -24.381 | -17.774 | -18.486 | -16.039 | -13.478 | -13.135 | -14.248 | -11.371 | -10.411 | -9.206 | -8.415 | -3.935 | -3.441 | -3.793 | -1.341 | -2.49 | -2.035 | -2.046 |
| Operating Income Ratio
| 0 | 0 | -63.745 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.934 | -3.411 | -13.477 | -9.053 |
| Total Other Income Expenses Net
| 3.844 | 2.901 | 1.989 | 3.082 | -0.016 | 1.828 | 1.382 | 0.661 | 0.26 | 0.077 | 0.004 | 0.019 | -57.921 | -23.208 | 0.586 | 0 | 0 | 0.001 |
| Income Before Tax
| -20.537 | -14.873 | -16.497 | -12.957 | -11.61 | -11.307 | -12.866 | -10.71 | -10.151 | -9.129 | -8.349 | -3.902 | -61.358 | -26.997 | -0.755 | -2.49 | -2.035 | -2.045 |
| Income Before Tax Ratio
| 0 | 0 | -56.886 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.526 | -3.411 | -13.477 | -9.049 |
| Income Tax Expense
| 0 | -0.044 | 3.752 | -0.04 | -1.884 | -1.828 | 0.998 | -0.661 | -0.26 | -0.077 | -0.066 | -0.056 | 57.917 | 23.204 | -0.586 | -2.49 | -2.035 | -0.001 |
| Net Income
| -20.537 | -14.873 | -16.497 | -12.957 | -11.61 | -9.479 | -13.864 | -10.049 | -9.891 | -9.052 | -8.349 | -3.902 | -61.358 | -26.997 | -0.755 | -2.49 | -2.035 | -2.045 |
| Net Income Ratio
| 0 | 0 | -56.886 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.526 | -3.411 | -13.477 | -9.049 |
| EPS
| -0.34 | -0.25 | -0.28 | -0.24 | -0.28 | -0.23 | -0.34 | -0.25 | -0.24 | -0.22 | -0.22 | -0.1 | -1.59 | -0.73 | -0.026 | -0.087 | -0.071 | -0.071 |
| EPS Diluted
| -0.34 | -0.25 | -0.28 | -0.24 | -0.28 | -0.23 | -0.34 | -0.25 | -0.24 | -0.22 | -0.22 | -0.1 | -1.59 | -0.73 | -0.026 | -0.087 | -0.071 | -0.071 |
| EBITDA
| -24.336 | -17.774 | -18.447 | -16.039 | -13.425 | -13.083 | -14.199 | -11.327 | -10.372 | -9.169 | 72.653 | -3.879 | 54.499 | 19.424 | -1.342 | -2.49 | -2.035 | -2.046 |
| EBITDA Ratio
| 0 | 0 | -63.61 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.935 | -3.411 | -13.477 | -9.053 |